Corbus Pharmaceuticals (CRBP) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates ...
Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) fell ~12% in the premarket on Friday after the company announced data from its US and UK-conducted first-in-human dose escalation clinical study of ...
In a report released on February 11, Brian Abrahams from RBC Capital maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report), with a price target of $65.00. The company’s ...
Shares of CRBP stock opened at $6.79 on Wednesday. The stock’s 50-day simple moving average is $9.44 and its 200-day simple moving average is $18.99. The firm has a market capitalization of $82. ...
Shares of CRBP stock opened at $6.79 on Friday. The stock’s 50 day simple moving average is $9.44 and its 200 day simple moving average is $18.99. Corbus Pharmaceuticals has a twelve month low ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback